Azatadina (nome comercial: Optimina) é um anti-histamínico de primeira geração e anticolinérgico que foi lançado pela Schering-Plough em 1973.[1][2]
Foi patenteado em 1967.[3] Tem sido sucedido por outros anti-histamínicos[4] e as aprovações de marketing foram amplamente retiradas.[5][6][7][8][9]
Ver também
Referências
- ↑ Katelaris, C. (1990). «Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis». Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–107. PMID 1982614
- ↑ Small, P.; Barrett, D.; Biskin, N. (1990). «Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation». Annals of Allergy. 64 (2 Pt 1): 129–131. PMID 1968324
- ↑ Azatadine, Villani, F. J.; Caldwell, W. Patente E.U.A. 3 326 924 (1967).
- ↑ Horak F. Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4 in Allergy Frontiers:Therapy and Prevention. Volume 5 of Allergy Frontiers. Eds Pawankar R et al Springer Science & Business Media, 2010 ISBN 9784431993629
- ↑ Drugs.com Drugs.com listing for Azatadine Page accessed July 3, 2015
- ↑ Federal Register 2005 Food and Drug Administration Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications 70 FR 10651
- ↑ Federal Register 2007 Food and Drug Administration Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions 72 FR 8184
- ↑ Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals United Nations – New York, 2005
- ↑ FDA OGD Suitability Tracking Report (Sorted by Drug Name) Page accessed July 3, 2015
